Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Increases By 209.8%

Key Points

• Short interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) surged by 209.8% in September, raising total short interest to 221,500 shares.
• Despite the increase in short interest, Bayer's stock has only slightly decreased by 0.3% and currently trades at $7.82, with a market cap of $30.73 billion.
• Analysts have upgraded Bayer's rating to "Strong Buy", reflecting positive sentiment, with a consensus rating highlighting three "Strong Buy" and one "Buy" ratings.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 221,500 shares, an increase of 209.8% from the September 15th total of 71,500 shares. Based on an average daily trading volume, of 649,200 shares, the short-interest ratio is currently 0.3 days. Based on an average daily trading volume, of 649,200 shares, the short-interest ratio is currently 0.3 days.

Bayer Aktiengesellschaft Stock Down 0.3%

Bayer Aktiengesellschaft stock opened at $7.82 on Friday. The stock has a market cap of $30.73 billion, a PE ratio of -8.06, a P/E/G ratio of 3.58 and a beta of 0.90. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.13 and a quick ratio of 0.73. The stock's fifty day moving average is $8.09 and its two-hundred day moving average is $7.46. Bayer Aktiengesellschaft has a 1-year low of $4.79 and a 1-year high of $8.70.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.35 EPS for the quarter, beating analysts' consensus estimates of $0.25 by $0.10. Bayer Aktiengesellschaft had a positive return on equity of 15.44% and a negative net margin of 7.61%.The business had revenue of $12.42 billion for the quarter, compared to the consensus estimate of $10.79 billion. On average, sell-side analysts expect that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Analysts Set New Price Targets

BAYRY has been the topic of several recent research reports. Wall Street Zen raised shares of Bayer Aktiengesellschaft from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Zacks Research raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 30th. Three analysts have rated the stock with a Strong Buy rating and one has given a Buy rating to the company's stock. According to MarketBeat.com, Bayer Aktiengesellschaft currently has a consensus rating of "Strong Buy".

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.